{"id":823712,"date":"2025-03-10T12:58:14","date_gmt":"2025-03-10T16:58:14","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/ntla-investors-have-opportunity-to-lead-intellia-therapeutics-inc-securities-fraud-lawsuit-4\/"},"modified":"2025-03-10T12:58:14","modified_gmt":"2025-03-10T16:58:14","slug":"ntla-investors-have-opportunity-to-lead-intellia-therapeutics-inc-securities-fraud-lawsuit-4","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/ntla-investors-have-opportunity-to-lead-intellia-therapeutics-inc-securities-fraud-lawsuit-4\/","title":{"rendered":"NTLA Investors Have Opportunity to Lead Intellia Therapeutics, Inc. Securities Fraud Lawsuit"},"content":{"rendered":"
\n

PR Newswire<\/p>\n<\/p><\/div>\n

\n

\n
\n NEW YORK<\/span>
\n <\/span>, March 10, 2025<\/span><\/span> \/PRNewswire\/ — Rosen Law Firm, a global investor rights law firm, announces that a shareholder filed a class action on behalf of purchasers of securities of Intellia Therapeutics, Inc. (NASDAQ: NTLA) between July 30, 2024<\/span> and January 8, 2025<\/span>, both dates inclusive (the “Class Period”). A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than April 14, 2024<\/span>.<\/p>\n

\n

\n
\n \"LOGO
\n <\/a>\n <\/p>\n<\/p><\/div>\n

So what: If you purchased Intellia securities\u00a0during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.<\/p>\n

What to do next: To join the Intellia class action, go to\u00a0 https:\/\/rosenlegal.com\/submit-form\/?case_id=35009<\/a>\u00a0mailto:<\/a>or call Phillip Kim, Esq.<\/span> toll-free at 866-767-3653 or email case@rosenlegal.com<\/a> for information on the class action. A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than April 14, 2025<\/span>. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.<\/p>\n

Why Rosen Law: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources, or any meaningful peer recognition. Many of these firms do not actually litigate securities class actions, but are merely middlemen that refer clients or partner with law firms that actually litigate the cases. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm achieved the largest ever securities class action settlement against a Chinese Company at the time. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered hundreds of millions of dollars for investors. In 2019 alone the firm secured over $438 million<\/span> for investors. In 2020, founding partner Laurence Rosen<\/span> was named by law360 as a Titan of Plaintiffs’ Bar. Many of the firm’s attorneys have been recognized by Lawdragon and Super Lawyers.<\/p>\n

Details of the case: According to the lawsuit, throughout the Class Period, defendants provided investors with material information concerning Intellia’s Phase 1\/2 study evaluating NTLA-3001 for the treatment of alpha-1 antitrypsin deficiency (AATD)-associated lung disease. Defendants’ statements included, among other things, confidence in Intellia’s timeline for the aforementioned study, specifically that Intellia expected to dose the first patient in the second half of 2024. Defendants failed to disclose inter alia<\/i> that the demand for viral-based editing was rapidly dwindling as non-viral delivery methods became a main target of the scientific research community due to their cost-effectiveness and more efficient development, thus making NTLA-3001 an inefficient program for Intellia to maintain. When the true details entered the market, the lawsuit claims that investors suffered damages.<\/p>\n

To join the Intellia class action, go to https:\/\/rosenlegal.com\/submit-form\/?case_id=35009<\/a>mailto:<\/a>or call Phillip Kim, Esq.<\/span> toll-free at 866-767-3653 or email case@rosenlegal.com<\/a> for information on the class action. A class action lawsuit has already been filed.<\/p>\n

No Class Has Been Certified. Until a class is certified, you are not represented by counsel unless you retain one. You may select counsel of your choice. You may also remain an absent class member and do nothing at this point. An investor’s ability to share in any potential future recovery is not dependent upon serving as lead plaintiff.<\/p>\n

Follow us for updates on LinkedIn: https:\/\/www.linkedin.com\/company\/the-rosen-law-firm<\/a>, on Twitter: https:\/\/twitter.com\/rosen_firm<\/a> or on Facebook: https:\/\/www.facebook.com\/rosenlawfirm\/<\/a>.<\/p>\n

Attorney Advertising. Prior results do not guarantee a similar outcome.<\/p>\n

Contact Information:<\/p>\n

\u00a0\u00a0\u00a0\u00a0\u00a0 Laurence Rosen, Esq.<\/span>
\u00a0\u00a0\u00a0\u00a0\u00a0 Phillip Kim, Esq.<\/span>
\u00a0\u00a0\u00a0\u00a0\u00a0 The Rosen Law Firm, P.A.
\u00a0\u00a0\u00a0\u00a0\u00a0 275 Madison Avenue, 40th Floor
\u00a0\u00a0\u00a0\u00a0\u00a0 New York, NY<\/span> 10016
\u00a0\u00a0\u00a0\u00a0\u00a0 Tel: (212) 686-1060
\u00a0\u00a0\u00a0\u00a0\u00a0 Toll Free: (866) 767-3653
\u00a0\u00a0\u00a0\u00a0\u00a0 Fax: (212) 202-3827
\u00a0\u00a0\u00a0\u00a0\u00a0 case@rosenlegal.com<\/a>
\u00a0\u00a0\u00a0\u00a0\u00a0 www.rosenlegal.com<\/a><\/p>\n

\n \"Cision\" View original content to download multimedia:https:\/\/www.prnewswire.com\/news-releases\/ntla-investors-have-opportunity-to-lead-intellia-therapeutics-inc-securities-fraud-lawsuit-302396617.html<\/a><\/p>\n

SOURCE THE ROSEN LAW FIRM, P. A.<\/p>\n<\/p><\/div>\n

\"\"<\/p>\n","protected":false},"excerpt":{"rendered":"

PR Newswire NEW YORK , March 10, 2025 \/PRNewswire\/ — Rosen Law Firm, a global investor rights law firm, announces that a shareholder filed a class action on behalf of purchasers of securities of Intellia Therapeutics, Inc. (NASDAQ: NTLA) between July 30, 2024 and January 8, 2025, both dates inclusive (the “Class Period”). A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than April 14, 2024. So what: If you purchased Intellia securities\u00a0during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement. What to do next: To join the Intellia class … <\/p>\n

Continue reading “NTLA Investors Have Opportunity to Lead Intellia Therapeutics, Inc. Securities Fraud Lawsuit”<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-823712","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"\nNTLA Investors Have Opportunity to Lead Intellia Therapeutics, Inc. Securities Fraud Lawsuit - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/ntla-investors-have-opportunity-to-lead-intellia-therapeutics-inc-securities-fraud-lawsuit-4\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"NTLA Investors Have Opportunity to Lead Intellia Therapeutics, Inc. Securities Fraud Lawsuit - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"PR Newswire NEW YORK , March 10, 2025 \/PRNewswire\/ — Rosen Law Firm, a global investor rights law firm, announces that a shareholder filed a class action on behalf of purchasers of securities of Intellia Therapeutics, Inc. (NASDAQ: NTLA) between July 30, 2024 and January 8, 2025, both dates inclusive (the “Class Period”). A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than April 14, 2024. So what: If you purchased Intellia securities\u00a0during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement. What to do next: To join the Intellia class … Continue reading "NTLA Investors Have Opportunity to Lead Intellia Therapeutics, Inc. Securities Fraud Lawsuit"\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/ntla-investors-have-opportunity-to-lead-intellia-therapeutics-inc-securities-fraud-lawsuit-4\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2025-03-10T16:58:14+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mma.prnewswire.com\/media\/2598307\/32a64817_10ba_407b_947c_76bd790799f6_Logo.jpg\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ntla-investors-have-opportunity-to-lead-intellia-therapeutics-inc-securities-fraud-lawsuit-4\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ntla-investors-have-opportunity-to-lead-intellia-therapeutics-inc-securities-fraud-lawsuit-4\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"NTLA Investors Have Opportunity to Lead Intellia Therapeutics, Inc. Securities Fraud Lawsuit\",\"datePublished\":\"2025-03-10T16:58:14+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ntla-investors-have-opportunity-to-lead-intellia-therapeutics-inc-securities-fraud-lawsuit-4\\\/\"},\"wordCount\":696,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ntla-investors-have-opportunity-to-lead-intellia-therapeutics-inc-securities-fraud-lawsuit-4\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mma.prnewswire.com\\\/media\\\/2598307\\\/32a64817_10ba_407b_947c_76bd790799f6_Logo.jpg\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ntla-investors-have-opportunity-to-lead-intellia-therapeutics-inc-securities-fraud-lawsuit-4\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ntla-investors-have-opportunity-to-lead-intellia-therapeutics-inc-securities-fraud-lawsuit-4\\\/\",\"name\":\"NTLA Investors Have Opportunity to Lead Intellia Therapeutics, Inc. Securities Fraud Lawsuit - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ntla-investors-have-opportunity-to-lead-intellia-therapeutics-inc-securities-fraud-lawsuit-4\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ntla-investors-have-opportunity-to-lead-intellia-therapeutics-inc-securities-fraud-lawsuit-4\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mma.prnewswire.com\\\/media\\\/2598307\\\/32a64817_10ba_407b_947c_76bd790799f6_Logo.jpg\",\"datePublished\":\"2025-03-10T16:58:14+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ntla-investors-have-opportunity-to-lead-intellia-therapeutics-inc-securities-fraud-lawsuit-4\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ntla-investors-have-opportunity-to-lead-intellia-therapeutics-inc-securities-fraud-lawsuit-4\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ntla-investors-have-opportunity-to-lead-intellia-therapeutics-inc-securities-fraud-lawsuit-4\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mma.prnewswire.com\\\/media\\\/2598307\\\/32a64817_10ba_407b_947c_76bd790799f6_Logo.jpg\",\"contentUrl\":\"https:\\\/\\\/mma.prnewswire.com\\\/media\\\/2598307\\\/32a64817_10ba_407b_947c_76bd790799f6_Logo.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ntla-investors-have-opportunity-to-lead-intellia-therapeutics-inc-securities-fraud-lawsuit-4\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"NTLA Investors Have Opportunity to Lead Intellia Therapeutics, Inc. Securities Fraud Lawsuit\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"NTLA Investors Have Opportunity to Lead Intellia Therapeutics, Inc. Securities Fraud Lawsuit - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/ntla-investors-have-opportunity-to-lead-intellia-therapeutics-inc-securities-fraud-lawsuit-4\/","og_locale":"en_US","og_type":"article","og_title":"NTLA Investors Have Opportunity to Lead Intellia Therapeutics, Inc. Securities Fraud Lawsuit - Market Newsdesk","og_description":"PR Newswire NEW YORK , March 10, 2025 \/PRNewswire\/ — Rosen Law Firm, a global investor rights law firm, announces that a shareholder filed a class action on behalf of purchasers of securities of Intellia Therapeutics, Inc. (NASDAQ: NTLA) between July 30, 2024 and January 8, 2025, both dates inclusive (the “Class Period”). A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than April 14, 2024. So what: If you purchased Intellia securities\u00a0during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement. What to do next: To join the Intellia class … Continue reading \"NTLA Investors Have Opportunity to Lead Intellia Therapeutics, Inc. Securities Fraud Lawsuit\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/ntla-investors-have-opportunity-to-lead-intellia-therapeutics-inc-securities-fraud-lawsuit-4\/","og_site_name":"Market Newsdesk","article_published_time":"2025-03-10T16:58:14+00:00","og_image":[{"url":"https:\/\/mma.prnewswire.com\/media\/2598307\/32a64817_10ba_407b_947c_76bd790799f6_Logo.jpg","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ntla-investors-have-opportunity-to-lead-intellia-therapeutics-inc-securities-fraud-lawsuit-4\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ntla-investors-have-opportunity-to-lead-intellia-therapeutics-inc-securities-fraud-lawsuit-4\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"NTLA Investors Have Opportunity to Lead Intellia Therapeutics, Inc. Securities Fraud Lawsuit","datePublished":"2025-03-10T16:58:14+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ntla-investors-have-opportunity-to-lead-intellia-therapeutics-inc-securities-fraud-lawsuit-4\/"},"wordCount":696,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ntla-investors-have-opportunity-to-lead-intellia-therapeutics-inc-securities-fraud-lawsuit-4\/#primaryimage"},"thumbnailUrl":"https:\/\/mma.prnewswire.com\/media\/2598307\/32a64817_10ba_407b_947c_76bd790799f6_Logo.jpg","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ntla-investors-have-opportunity-to-lead-intellia-therapeutics-inc-securities-fraud-lawsuit-4\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/ntla-investors-have-opportunity-to-lead-intellia-therapeutics-inc-securities-fraud-lawsuit-4\/","name":"NTLA Investors Have Opportunity to Lead Intellia Therapeutics, Inc. Securities Fraud Lawsuit - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ntla-investors-have-opportunity-to-lead-intellia-therapeutics-inc-securities-fraud-lawsuit-4\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ntla-investors-have-opportunity-to-lead-intellia-therapeutics-inc-securities-fraud-lawsuit-4\/#primaryimage"},"thumbnailUrl":"https:\/\/mma.prnewswire.com\/media\/2598307\/32a64817_10ba_407b_947c_76bd790799f6_Logo.jpg","datePublished":"2025-03-10T16:58:14+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ntla-investors-have-opportunity-to-lead-intellia-therapeutics-inc-securities-fraud-lawsuit-4\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/ntla-investors-have-opportunity-to-lead-intellia-therapeutics-inc-securities-fraud-lawsuit-4\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ntla-investors-have-opportunity-to-lead-intellia-therapeutics-inc-securities-fraud-lawsuit-4\/#primaryimage","url":"https:\/\/mma.prnewswire.com\/media\/2598307\/32a64817_10ba_407b_947c_76bd790799f6_Logo.jpg","contentUrl":"https:\/\/mma.prnewswire.com\/media\/2598307\/32a64817_10ba_407b_947c_76bd790799f6_Logo.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ntla-investors-have-opportunity-to-lead-intellia-therapeutics-inc-securities-fraud-lawsuit-4\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"NTLA Investors Have Opportunity to Lead Intellia Therapeutics, Inc. Securities Fraud Lawsuit"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/823712","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=823712"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/823712\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=823712"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=823712"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=823712"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}